MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.
news, journals and articles from all over the world.
MD Anderson and Erasca announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway in cancer.